Blood test may predict who benefits from CAR-T for lymphoma

NCT ID NCT06352242

Recruiting now Knowledge-focused Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a blood test can predict how well CAR-T cell therapy works in people with diffuse large B-cell lymphoma. Researchers will take blood samples before and after treatment to look for a specific immune cell activity called trogocytosis. The goal is to find a pattern that tells doctors early on if the therapy is likely to succeed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple blood test that helps doctors predict which patients will respond well to CAR-T therapy for lymphoma.
What could go wrong: This is an early observational study, not a treatment trial. It may not find a reliable predictive signature, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

Clinical Investigation Center, University Hospital
RECRUITING

Montpellier, France
Clinical hematology department, University Hospital
RECRUITING

Montpellier, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.